These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36379378)

  • 21. Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.
    Shrivastava-Ranjan P; Flint M; Bergeron É; McElroy AK; Chatterjee P; Albariño CG; Nichol ST; Spiropoulou CF
    mBio; 2018 May; 9(3):. PubMed ID: 29717011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Strategies against Ebola Virus Infection.
    Liu CH; Hu YT; Wong SH; Lin LT
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.
    Ekins S; Lingerfelt MA; Comer JE; Freiberg AN; Mirsalis JC; O'Loughlin K; Harutyunyan A; McFarlane C; Green CE; Madrid PB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling Ebola virus dynamics: Implications for therapy.
    Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
    Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
    Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Garza NL; Donnelly G; Cazares LH; Soloveva V; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
    Antiviral Res; 2018 Mar; 151():50-54. PubMed ID: 29289664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a broad-spectrum antiviral with activity against Ebola virus.
    Aman MJ; Kinch MS; Warfield K; Warren T; Yunus A; Enterlein S; Stavale E; Wang P; Chang S; Tang Q; Porter K; Goldblatt M; Bavari S
    Antiviral Res; 2009 Sep; 83(3):245-51. PubMed ID: 19523489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ebola virus disease in the Democratic Republic of Congo.
    Maganga GD; Kapetshi J; Berthet N; Kebela Ilunga B; Kabange F; Mbala Kingebeni P; Mondonge V; Muyembe JJ; Bertherat E; Briand S; Cabore J; Epelboin A; Formenty P; Kobinger G; González-Angulo L; Labouba I; Manuguerra JC; Okwo-Bele JM; Dye C; Leroy EM
    N Engl J Med; 2014 Nov; 371(22):2083-91. PubMed ID: 25317743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
    Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
    Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action.
    Corona A; Strayer D; Distinto S; Daino GL; Paulis A; Tramontano E; Mitchell WM
    Antiviral Res; 2023 Apr; 212():105554. PubMed ID: 36804324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives towards antiviral drug discovery against Ebola virus.
    Mirza MU; Vanmeert M; Ali A; Iman K; Froeyen M; Idrees M
    J Med Virol; 2019 Dec; 91(12):2029-2048. PubMed ID: 30431654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Screening of Multiple Compounds against Ebola Virus.
    Dowall SD; Bewley K; Watson RJ; Vasan SS; Ghosh C; Konai MM; Gausdal G; Lorens JB; Long J; Barclay W; Garcia-Dorival I; Hiscox J; Bosworth A; Taylor I; Easterbrook L; Pitman J; Summers S; Chan-Pensley J; Funnell S; Vipond J; Charlton S; Haldar J; Hewson R; Carroll MW
    Viruses; 2016 Oct; 8(11):. PubMed ID: 27801778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga.
    Chiramel AI; Banadyga L; Dougherty JD; Falzarano D; Martellaro C; Brees D; Taylor RT; Ebihara H; Best SM
    J Infect Dis; 2016 Oct; 214(suppl 3):S355-S359. PubMed ID: 27511894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.
    Qiu X; Kroeker A; He S; Kozak R; Audet J; Mbikay M; Chrétien M
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5182-8. PubMed ID: 27297486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication.
    Reynard O; Nguyen XN; Alazard-Dany N; Barateau V; Cimarelli A; Volchkov VE
    Viruses; 2015 Dec; 7(12):6233-40. PubMed ID: 26633464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment.
    Chertow DS; Shekhtman L; Lurie Y; Davey RT; Heller T; Dahari H
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31963118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
    Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
    Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.